Tech Company Financing Transactions
Arsanis Funding Round
Arsanis closed a $15 million funding round on 4/27/2016. Investors included private investors.
Transaction Overview
Company Name
Announced On
4/27/2016
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$15,007,220
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 10 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
890 Winter St. 230
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Not Recorded
Overview
Arsanis (NASDAQ: ASNS) is a biosciences company developing infectious disease treatments based on bacterial protein and carbohydrate antigens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
René Russo
Chief Medical Officer
Chris Stevens
Chief Operating Officer
Michael Gray
Chief Scientific Officer
Eszter Magy
VP - Bus. Development
David Mantus
Browse more venture capital transactions:
Prev: 4/27/2016: Cardiac Insight venture capital transaction
Next: 4/27/2016: Jet Health venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs